Johnson & Johnson newly announced the US Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO (esketamine) CIII nasal spray for the treatment of adults living with major depressive disorder (MDD) who have not responded to at least two oral antidepressants.
Advertisement
Two therapies being developed for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus are affected.
ASPEN-06 analyzed the CD47 myeloid checkpoint inhibitor ALX148 in patients with HER2-overexpressing gastric cancer.
Dr. Liu discusses remaining questions, key considerations, and how the data might shape the field moving forward.
Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Gut microbiota modulates bleeding risk in pediatric patients with immune thrombocytopenia.
In EMERALD-1, investigators analyzed the combination of durvalumab plus bevacizumab and TACE versus placebo with TACE.
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
Results of NIR-B trial sheds light on the clinical utility of niraparib in patients with BRCA-mutated GI cancers.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
ASPEN-06 analyzed the CD47 myeloid checkpoint inhibitor ALX148 in patients with HER2-overexpressing gastric cancer.
In EMERALD-1, investigators analyzed the combination of durvalumab plus bevacizumab and TACE versus placebo with TACE.
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
Results of NIR-B trial sheds light on the clinical utility of niraparib in patients with BRCA-mutated GI cancers.
A novel auto-segmentation model and radiomics signature may help with preoperative clinical decision-making for GEP-NETs.
The study reinforces the potential of triplet blockade with casdozo, atezo, and bev as a viable approach for managing uHCC.
The Latest From Heme Today
Two therapies being developed for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus are affected.
Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Gut microbiota modulates bleeding risk in pediatric patients with immune thrombocytopenia.
ASH's efforts pertain to professional recruitment as well as to address unique medical issues in patient populations.
Clinicians have an important role in helping donation centers make the most of exciting advances and meet recent challenges.
The CRL is related to observations of a third-party manufacturing facility as part of a standard prelicense inspection.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.